Invited commentary: Lipoproteins and dementia - Is it the apolipoprotein A-I?

American Journal of Epidemiology

Volumn 165, Issue 9, 2007, Pages 993-997

  Scarmeas, Nikolaos ^a,b  

^a NewYork Presbyterian Hospital   (United States)

^b Taub Institute for Research on Alzheimer's Disease and the Aging Brain and the Gertrude H Sergievsky Center   (United States)

Author keywords

Alzheimer disease; Apolipoproteins; Dementia; Lipids

Indexed keywords

APOLIPOPROTEIN A1; HIGH DENSITY LIPOPROTEIN;

AGING POPULATION; EPIDEMIOLOGY; HEALTH RISK; LIPID; NERVOUS SYSTEM DISORDER; PROTEIN; RISK FACTOR;

AGE DISTRIBUTION; AGING; ASIA; DEMENTIA; DISEASE ASSOCIATION; DYSLIPIDEMIA; HUMAN; REVIEW; RISK ASSESSMENT; UNITED STATES;

AGING; APOLIPOPROTEIN A-I; CHOLESTEROL, HDL; DEMENTIA; HUMANS; INFLAMMATION; LIPOPROTEINS; RISK FACTORS;

HAWAII [UNITED STATES]; NORTH AMERICA; UNITED STATES;

EID: 34247140072     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwm033     Document Type: Review

References (71)

1. Small GW, Rabins PV, Barry PP, et al. Diagnosis and treatment of Alzheimer disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society. JAMA 1997;278:1363-71.
2. Morris JC. Dementia update 2005. Alzheimer Dis Assoc Disord 2005;19:100-17.
3. Evans DA, Funkenstein HH, Albert MS, et al. Prevalence of Alzheimer's disease in a community population of older persons. Higher than previously reported. JAMA1989;262:2551-6.
4. Brookmeyer R, Gray S, Kawas C. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am J Public Health 1998;88:1337-42.
5. Hebert LE, Scherr PA, Bienias JL, et al. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol 2003;60:1119-22.
6. Ernst RL, Hay JW. The US economic and social costs of Alzheimer's disease revisited. Am J Public Health 1994;84:1261-4.
7. Zhu CW, Scarmeas N, Torgan R, et al. Longitudinal study of effects of patient characteristics on direct costs in Alzheimer disease. Neurology 2006;67:998-1005.
8. Zhu CW, Scarmeas N, Torgan R, et al. Clinical characteristics and longitudinal changes of informal cost of Alzheimer's disease in the community. J Am Geriatr Soc 2006;54:1596-602.
9. Tschanz JT, Corcoran C, Skoog I, et al. Dementia: the leading predictor of death in a defined elderly population: the Cache County Study. Neurology 2004;62:1156-62.
10. Jurevics H, Morell P. Cholesterol for synthesis of myelin is made locally, not imported into brain. J Neurochem 1995;64:895-901.
11. Michikawa M. Cholesterol paradox: is high total or low HDL cholesterol level a risk for Alzheimer's disease? J Neurosci Res 2003;72:141-6.
12. Koudinov AR, Koudinova NV. Essential role for cholesterol in synaptic plasticity and neuronal degeneration. FASEB J 2001;15:1858-60.
13. Mauch DH, Nagler K, Schumacher S, et al. CNS synaptogenesis promoted by glia-derived cholesterol. Science 2001;294:1354-7.
14. Fan QW, Yu W, Senda T, et al. Cholesterol-dependent modulation of tau phosphorylation in cultured neurons. J Neurochem 2001;76:391-400.
15. Vetrivel KS, Cheng H, Lin W, et al. Association of gamma-secretase with lipid rafts in post-Golgi and endosome membranes. J Biol Chem 2004;279:44945-54.
16. Koudinov AR, Berezov TT, Kumar A, et al. Alzheimer's amyloid beta interaction with normal human plasma high density lipoprotein: association with apolipoprotein and lipids. Clin Chim Acta 1998;270:75-84.
17. Refolo LM, Malester B, LaFrancois J, et al. Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol Dis 2000;7:321-31.
18. Sparks DL, Scheff SW, Hunsaker JC 3rd, et al. Induction of Alzheimer-like beta-amyloid immunoreactivity in the brains of rabbits with dietary cholesterol. Exp Neurol 1994;126:88-94.
19. Simons M, Keller P, De Strooper B, et al. Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc Natl Acad Sci U S A 1998;95:6460-4.
20. Eckert GP, Kirsch C, Leutz S, et al. Cholesterol modulates amyloid beta-peptide's membrane interactions. Pharmacopsychiatry 2003;36(suppl 2):S136-43.
21. Cockerill GW, Huehns TY, Weerasinghe A, et al. Elevation of plasma high-density lipoprotein concentration reduces interleukin-1-induced expression of E-selectin in an in vivo model of acute inflammation. Circulation 2001;103:108-12.
22. Paterno R, Ruocco A, Postiglione A, et al. Reconstituted high-density lipoprotein exhibits neuroprotection in two rat models of stroke. Cerebrovasc Dis 2004;17:204-11.
23. Wolf H, Hensel A, Arendt T, et al. Serum lipids and hippocampal volume: the link to Alzheimer's disease? Ann Neurol 2004;56:745-8.
24. Whitmer RA, Sidney S, Selby J, et al. Midlife cardiovascular risk factors and risk of dementia in late life. Neurology 2005;64:277-81.
25. Kivipelto M, Helkala EL, Laakso MP, et al. Apolipoprotein E epsilon4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer disease. Ann Intern Med 2002;137:149-55.
26. Kivipelto M, Helkala EL, Laakso MP, et al. Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study. BMJ 2001;322:1447-51.
27. Kivipelto M, Ngandu T, Fratiglioni L, et al. Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease. Arch Neurol 2005;62:1556-60.
28. Kalmijn S, Foley D, White L, et al. Metabolic cardiovascular syndrome and risk of dementia in Japanese-American elderly men. The Honolulu-Asia Aging Study. Arterioscler Thromb Vasc Biol 2000;20:2255-60.
29. Moroney JT, Tang MX, Berglund L, et al. Low-density lipoprotein cholesterol and the risk of dementia with stroke. JAMA 1999;282:254-60.
30. Romas SN, Tang MX, Berglund L, et al. APOE genotype, plasma lipids, lipoproteins, and AD in community elderly. Neurology 1999;53:517-21.
31. Reitz C, Tang MX, Luchsinger J, et al. Relation of plasma lipids to Alzheimer disease and vascular dementia. Arch Neurol 2004;61:705-14.
32. Kuusisto J, Koivisto K, Mykkanen L, et al. Association between features of the insulin resistance syndrome and Alzheimer's disease independently of apolipoprotein E4 phenotype: cross sectional population based study. BMJ 1997;315:1045-9.
33. Li G, Shofer JB, Kukull WA, et al. Serum cholesterol and risk of Alzheimer disease: a community-based cohort study. Neurology 2005;65:1045-50.
34. Knittweis JW, McMullen WA, Romas SN, et al. The effect of apoE on dementia is not through atherosclerosis: The Rotterdam Study. Neurology 2000;54:2356-8.
35. Tan ZS, Seshadri S, Beiser A, et al. Plasma total cholesterol level as a risk factor for Alzheimer disease: the Framingham Study. Arch Intern Med 2003;163:1053-7.
36. Mielke MM, Zandi PP, Sjogren M, et al. High total cholesterol levels in late life associated with a reduced risk of dementia. Neurology 2005;64:1689-95.
37. van Exel E, de Craen AJ, Gussekloo J, et al. Association between high-density lipoprotein and cognitive impairment in the oldest old. Ann Neurol 2002;51:716-21.
38. Bonarek M, Barberger-Gateau P, Letenneur L, et al. Relationships between cholesterol, apolipoprotein E polymorphism and dementia: a cross-sectional analysis from the PAQUID study. Neuroepidemiology 2000;19:141-8.
39. Merched A, Xia Y, Visvikis S, et al. Decreased high-density lipoprotein cholesterol and serum apolipoprotein AI concentrations are highly correlated with the severity of Alzheimer's disease. Neurobiol Aging 2000;21:27-30.
40. Abbott RD, Sharp DS, Burchfiel CM, et al. Cross-sectional and longitudinal changes in total and high-density-lipoprotein cholesterol levels over a 20-year period in elderly men: the Honolulu Heart Program. Ann Epidemiol 1997;7:417-24.
41. Ferrara A, Barrett-Connor E, Shan J. Total, LDL, and HDL cholesterol decrease with age in older men and women. The Rancho Bernardo Study 1984-1994. Circulation 1997;96:37-43.
42. Notkola IL, Sulkava R, Pekkanen J, et al. Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer's disease. Neuroepidemiology 1998;17:14-20.
43. Launer LJ, White LR, Petrovitch H, et al. Cholesterol and neuropathologic markers of AD: a population-based autopsy study. Neurology 2001;57:1447-52.
44. Pappolla MA, Bryant-Thomas TK, Herbert D, et al. Mild hypercholesterolemia is an early risk factor for the development of Alzheimer amyloid pathology. Neurology 2003;61:199-205.
45. Kuriyama M, Takahashi K, Yamano T, et al. Low levels of serum apolipoprotein A I and A II in senile dementia. Jpn J Psychiatry Neurol 1994;48:589-93.
46. Kawano M, Kawakami M, Otsuka M, et al. Marked decrease of plasma apolipoprotein AI and AII in Japanese patients with late-onset non-familial Alzheimer's disease. Clin Chim Acta 1995;239:209-11.
47. Saczynski JS, White L, Peila RL, et al. The relation between apolipoprotein A-I and dementia: The Honolulu-Asia Aging Study. Am J Epidemiol 2007;165:985-92.
48. Knopman DS, DeKosky ST, Cummings JL, et al. Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001;56:1143-53.
49. Leroy A, Dallongeville J, Fruchart JC. Apolipoprotein A-I-containing lipoproteins and atherosclerosis. Curr Opin Lipidol 1995;6:281-5.
50. Rosenson RS. Beyond low-density lipoprotein cholesterol. A perspective on low high-density lipoprotein disorders and Lp(a) lipoprotein excess. Arch Intern Med 1996;156:1278-84.
51. Schultz JR, Verstuyft JG, Gong EL, et al. Protein composition determines the anti-atherogenic properties of HDL in transgenic mice. Nature 1993;365:762-4.
52. von Eckardstein A, Fischer F, Schulte H, et al. Association of serum apolipoprotein A-I (but not high-density lipoprotein cholesterol) with healed myocardial infarction in men independent of serum insulin and C-peptide. Am J Cardiol 2001;88:723-6.
53. Luc G, Bard JM, Ferrieres J, et al. Value of HDL cholesterol, apolipoprotein A-I, lipoprotein A-I, and lipoprotein A-I/A-II in prediction of coronary heart disease: the PRIME Study. Prospective Epidemiological Study of Myocardial Infarction. Arterioscler Thromb Vasc Biol 2002;22:1155-61.
54. Sharp DS, Burchfiel CM, Rodriguez BL, et al. Apolipoprotein A-1 predicts coronary heart disease only at low concentrations of high-density lipoprotein cholesterol: an epidemiological study of Japanese-Americans. Int J Clin Lab Res 2000;30:39-48.
55. Borghini I, Barja F, Pometta D, et al. Characterization of subpopulations of lipoprotein particles isolated from human cerebrospinal fluid. Biochim Biophys Acta 1995;1255:192-200.
56. Pitas RE, Boyles JK, Lee SH, et al. Lipoproteins and their receptors in the central nervous system. Characterization of the lipoproteins in cerebrospinal fluid and identification of apolipoprotein B,E(LDL) receptors in the brain. J Biol Chem 1987;262:14352-60.
57. Roheim PS, Carey M, Forte T, et al. Apolipoproteins in human cerebrospinal fluid. Proc Natl Acad Sci U S A 1979;76:4646-9.
58. Fagan AM, Younkin LH, Morris JC, et al. Differences in the Abeta40/Abeta42 ratio associated with cerebrospinal fluid lipoproteins as a function of apolipoprotein E genotype. Ann Neurol 2000;48:201-10.
59. Harr SD, Uint L, Hollister R, et al. Brain expression of apolipoproteins E, J, and A-I in Alzheimer's disease. J Neurochem 1996;66:2429-35.
60. Song H, Saito K, Seishima M, et al. Cerebrospinal fluid apo E and apo A-I concentrations in early- and late-onset Alzheimer's disease. Neurosci Lett 1997;231:175-8.
61. Boyles JK, Zoellner CD, Anderson LJ, et al. A role for apolipoprotein E, apolipoprotein A-I, and low density lipoprotein receptors in cholesterol transport during regeneration and remyelination of the rat sciatic nerve. J Clin Invest 1989;83:1015-31.
62. Koudinov A, Matsubara E, Frangione B, et al. The soluble form of Alzheimer's amyloid beta protein is complexed to high density lipoprotein 3 and very high density lipoprotein in normal human plasma. Biochem Biophys Res Commun 1994;205:1164-71.
63. Wisniewski T, Golabek AA, Kida E, et al. Conformational mimicry in Alzheimer's disease. Role of apolipoproteins in amyloidogenesis. Am J Pathol 1995;147:238-44.
64. Stuart WD, Krol B, Jenkins SH, et al. Structure and stability of apolipoprotein J-containing high-density lipoproteins. Biochemistry 1992;31:8552-9.
65. Golabek A, Marques MA, Lalowski M, et al. Amyloid beta binding proteins in vitro and in normal human cerebrospinal fluid. Neurosci Lett 1995;191:79-82.
66. Zlokovic BV, Martel CL, Mackic JB, et al. Brain uptake of circulating apolipoproteins J and E complexed to Alzheimer's amyloid beta. Biochem Biophys Res Commun 1994;205:1431-7.
67. Zlokovic BV, Martel CL, Matsubara E, et al. Glycoprotein 330/megalin: probable role in receptor-mediated transport of apolipoprotein J alone and in a complex with Alzheimer disease amyloid beta at the blood-brain and blood-cerebrospinal fluid barriers. Proc Natl Acad Sci U S A 1996;93:4229-34.
68. Navab M, Anantharamaiah GM, Fogelman AM. The role of high-density lipoprotein in inflammation. Trends Cardiovasc Med 2005;15:158-61.
69. Navab M, Hama SY, Cooke CJ, et al. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: step 1. J Lipid Res 2000;41:1481-94.
70. Garner B, Waldeck AR, Witting PK, et al. Oxidation of high density lipoproteins. II. Evidence for direct reduction of lipid hydroperoxides by methionine residues of apolipoproteins AI and AII. J Biol Chem 1998;273:6088-95.
71. Kontush A, Chapman MJ. Antiatherogenic small, dense HDL - guardian angel of the arterial wall? Nat Clin Pract Cardiovasc Med 2006;3:144-53.